Business
Covalon Delays Filing of Interim Financial Statements Due to Delays Related to COVID-19 and Provides Business Update
Covalon Delays Filing of Interim Financial Statements Due to Delays Related to COVID-19 an...
About this update from Covalon Technologies Ltd.
[{"type":"text","content":"\n\n\n\nCovalon Delays Filing of Interim Financial Statements Due to Delays Related to COVID-19 and Provides Business Update\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nMISSISSAUGA, ON, May 29, 2020\n\n\n\nMISSISSAUGA, ON, May 29, 2020 /CNW/ - Covalon Technologies Ltd. (the \"Company\" or \"Covalon\") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announced today that it is relying on the exemption provided in Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Financial Requirements (and similar exemptions provided by the other Canadian securities regulators) to postpone the filing of the interim financial statements and management's discussion and analysis for the quarter ended March 31st, 2020. The Company expects to file the Documents within the 45-day postponement period.\n\n \n \n \n \n \n \n\n \nUntil the Company has filed the Documents, members of the Company's management and other insiders are subject to an insider trading black-out policy that reflects the principles in section 9 of National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.\nAn update on material business developments since the filing of the Company's interim financial report for the period ended December 31st, 2019 is described below, certain of which have already been disclosed in prior press releases:\nThe CovaGuard™ Technology\nOn March 31st, 2020, Covalon announced CovaGuard™, its new antimicrobial technology platform. The CovaGuard antimicrobial technology (\"CovaGuard\") is specifically formulated to be effective at killing pathogens on contact with the added benefit of providing persistent protection by trapping and deactivating microbes over an extended period. \n\"I am very pleased with the ongoing business discussions around our CovaGuard technology and the resulting products that have been cleared for sale,\" said Brian Pedlar, Covalon's Chief Executive Officer. \"CovaGuard has the opportunity to be a strong platform technology for Covalon and we are in discussi...